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-4 FEIV TE.IRS AGO it seemed highly unlikely 
that homotmnsplantation of tissues and or- 
gans was so soon to play a significant role 
in the medical armamentarium, despite an 
enormous quantity of research dating back 
more than a half century. The view persisted 
that the severity and perseverance of homo- 
graft reiection constituted an insurmountable 
barrier t o  the successful use of alien tissue. 
Since 1961, these attitudes have undergone 
a remarkable change. illore than a hundred 
patients throughout the \vorld have had sjgnif- 
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icant prolongation of life through functioq- 
ing renal homografts. Long-term sun-ival has 
been obtained in laboratory animals after 
homotransplantation of other organs including 
the liver, lung, heart, and spleen. Earlier un- 
warranted pessimism concerning the fate of 
homografts has been replaced by what, in 
some circles, may be viewed as overoptimism 
since the life expectancy of patients or animals 
n i th  transplants tolerated over a long period 
of time is not yet known. 
In this communication, a brief account will 
be given of the results of clinical renal homo- 
transplantation a t  the University of Colorado 
Jledical Center, focusing attention only upon 
those patients treated from 20 t o  36 months 
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ago. -1 brief description of the encouraging 
results niter esperimental liver transplantation 
\\-ill also be included. 
TABLE I 
Rrnclts in 64 Conseczctive Patients T r e ~ t e d  with Renal 
Howlografts Obtained from Living Volunteer Donors 
During the lnterval from November 1962 to March 
1964; Sunival is to the First Part o f  Decernbt-7. 1965 
RENAL HOMOTRANSPLANTATION 
Sixt!--four consecutive patients were treated 
with renal homografts from living volunteer 
donors betlreen November 1962 and March 
1964.l.' Rejection was controlled with azathi- 
oprine (Imuran), prednisone, actinomycin C, 
and in one case with total body irradiation. 
The greatest risk from failure due to  homo- 
graft malfunction or to toxicity from irnrnu- 
nosuppressive agents is during the first few 
postoperaave months when variable degrees 
of rejection are common. The  phenomenon 
of rejection has proved to be reversible with 
intensification of immunosuppressive therapy. 
Later, the aggressiveness of therapy can very 
often be relaxed; nevertheless, many patients 
now living for a long time after operation 
have had continuing evidence of low-grade 
host-against-graft immunologic activity. 
The results in these 64 patients are sum- 
marized in Table I. Thirty-seven (58 per cent) 
of the 64 patients lived for at least one 
year after operation. Three subsequently died 
after 13 1/2, 22, and 23 1/2 months. In all 3 cases, 
renal function was still suflicient to maintain 
active life, but other complications of chronic 
liver injury (possibly drug induced) and 
sepsis were the direct cause of death. The 
remaining 34 patients (53.1 per cent) are still 
alive after 20 to 36 months. Twenty-three 
of these patients have already passed the 2-year 
level of convalescence. 
The  best results were in the 46 cases in 
which the kidney was provided by a blood 
relative (Table I). Thirty-one of these pa- 
tients (67 per cent) lived for at least l year; 
30 (65.2 per cent) are still alive with an 
average survival of 28 months. In contrast, 
only 6 of the 18 patients (33 per cent) who 
received kidnevs from nonrelated donors lived 
beyond 1 year, and 2 have subsequently died. 
Kidney function is adequate in all of the 
currently surviving patients although in some 
there has been a gradual decline in the quality 
of renal excretion and in others continuous 
stable function has required the recurrent 
administration of potentially toxic doses of 
prednisone. These clinical findings suggest 
that future death will occur at a gradual rate 
due to continued low-grade rejection. This 
impression is strengthened by study (by Dr. 
Lived Died After 
No. 1 Year 1 Year Alive 
Tom1 Series 64 37 3 * 34t 
Related donors 16 3 1 1 30 
Nonrelated donors 18 6 2 6 
'Late deaths at 1 3  X, 22, and 23X months. 
tOf these patients 23 are from 2 to more than 3 
years. The other 11 are between 20 and 24 months. 
Ken A. Porter, St. Mary's Hospital and Medi- 
cal School, London) of biopsies taken from 21 
of the homografts obtained after approxi- 
mately two years' residence in their human 
hosts. The  following are some of Dr. Porter's 
findings. 
Three of the homografts were normal. In 
the others, there was an assortment of abnor- 
malities often not associated with impairment 
of renal function. 
There were vascular lesions which had 
many forms: fibrous intimal thickening of 
interlobular arteries often with rupture or 
duplication of the internal elastic lamina; de- 
position of a hyaline-like substance in the 
subintimal layer of afferent arterioles; and 
deposition of the PAS-positive hyaline ma- 
terial in the glomerular capillaries. 
The homografts with vascular lesions fre- 
quently had other secondary morphologic 
changes: fibrosis of the glomerular tuft, peri- 
glomerular fibrosis, interstitial fibrosis, or 
tubular atrophy. 
In addition, the majority of the homografts 
contained focal accumulations of mononuclear 
cells. Ten  to 40 per cent of these cells con- 
sisted of the pyronine positive variety, which 
are traditionally found in acute homograft re- 
jection. In homografts functioning over a 
period of time such cells seem to be reasonably 
u-ell-tolerated. 
HOMOTRANSPLAVTATION OF THE LIVER 
There are two general methods for whole 
organ transplantation of the liver. One in- 
volves the extirpation of the host animal's 
own liver and replacement with an organ 
obtained from a nonrelated mongrel animal. 
The homograft is revascularized in a normal 
manner. Using immunosuppressive regimens 
similar to those employed for the kidney, 
survival in our laboratories has been obtained 
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for as long as 20  month^.^ Most of the general 
problems encountered are comparable to  
those already well-defined after transplanta- 
tion of the kidney. 
In spite of these successful experiments, 7 
efforts a t  human orthotopic transplantation 
in Denver 2nd elsewhere have failed; maxi- 
mum survival has been 23 days. These experi- 
ences have defined problems of technique, 
organ preservation, and control of coagula- 
tion which must be successfully managed in 
future trials. 
An alternative method of liver transplanta- 
tion, which may some day have application 
for the treatment of hepatic failure due to 
benign liver disease, is heterotopic uansplanta- 
tion.' Here, the host liver is not removed and 
the homograft is placed in some abnormal 
location such as the pelvis, left upper quad- 
rant, or one of the paravertebral gutters. Al- 
though the concept of heterotopic transplan- 
tation is an attractive one, since residual func- 
tion in the host liver is not sacrificed, i t  is still 
not known whether this approach is a sound 
one. Recent laboratory investigations have 
shown that when two livers are present in the 
same animal each may be responsible for injury 
to the other, apparently by  a mechanism of 
competition for nutritional metabolites. Such 
physiologic problems as well as those con- 
cerned with the space limitations in a recipi- 
ent's abdomen make it  necessary to defer 
judgment about the future potential useful- 
This is a condensed version of tb 
~cientific session-Ed. 
ness of this approach. Clinical heterotopic 
transplantation is known to have been 
attempted in at least 6 institutions, with maxi- 
mum survival of only 5 weeks. 
SUMMARY 
C 
More than half of an original series of 64 
patients receiving renal transplants, treated at 
the University of Colorado Medical Center 
from 20 to 36 months ago, are still alive. The  
ultimate life expectancy of these remaining 
patients is not known. Significant improve- 
ment in results after liver transplantation has 
been documented in animals, but long-term 
success has not yet been obtained in patients. 
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